Law360, New York (November 18, 2009) -- A U.S. Food and Drug Administration staff review has found that certain gadolinium-based contrast agents used during MRI procedures may pose more of a risk of a fatal skin disease than other agents on the market.
The FDA’s drug safety unit determined in the review that the greatest risk of developing the disease, known as nephrogenic systemic fibrosis, was tied to GE Healthcare’s Omniscan, Bayer AG’s...
